Bibliografía del artículo
1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993.
2. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993.
3. Turner RC. The UK Prospective Diabetes Study: A review. Diabetes Care 21(Suppl.3):C35-38, 1998.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998.
5. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 30:S42-S47, 2007.
7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 30(Suppl.1):S4-41, 2007.
8. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme forms of insulin resistance. Diabetes Care 28(5):1240-1244, 2005.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 30(Suppl.1):S42-47, 2007.
10. American Association of Clinical Endocrinologists. State of diabetes in America. Disponible en: www.stateofdiabetes.com/blood_sugar_levels.html#. Accessed May 16, 2007.
11. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144:465-474, 2006.
12. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med 141:272-281, 2004.
13. Sayda SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342, 2004.
14. Bolli GB. Type 1 diabetes: Effective insulin strategies with less hypoglycemia. Postgraduate Medicine 13-20, 2004.
15. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351:1106-1118, 2004.
16. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758-767, 2001.
17. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et. al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002.
18. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002.
19. Dailey G. new strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther 26:889-901, 2004.
20. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29(8):1963-72, 2006.
21. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53:513-519, 2004.
22. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 81:87-100, 2002.
23. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 89:1548-1554, 2004.
24. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year perspective. Medicine (Baltimore) 83:209-222, 2004.
25. Oral EA, Simha V, Ruiz E, Reitman ML, Taylor SI, Gorden P, Garg A, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-578, 2002.
26. Musso C, Cochran E, Javor E, Young J, DePaoli A, Gorden P. The long term effect of recominant methionyl human leptin (r-metHuLeptin) therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism 54(2):255-263, 2005.
27. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 294:739-745, 1976.
28. Neal JM Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocrine Practive 11(5):305-307, 2005.
29. Wafa W, Khan M. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care 29(9):2175, 2006.
30. Jorgensen K, Hansen A, Buschard K. Five fold increase of insulin concentration delays in the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Research and Clinical Practice 50:161-167, 2000.
31. Binder C, Brange J. Insulin chemistry and pharmacokinetics. En: Porte D Jr, Sherwin RS, editors. Ellenberg's and Rifkin's Diabetes Mellitus. 5a ed. Stamford, CT. Appleton and Lange, p. 689, 1997.
32. Ballani P, Tran M, Navar M, Davidson M. Clinical experience with U-500 regular insulin in obese, markedly insulin resistant type 2 diabetic patients. Diabetes Care 29(11):2504-2505, 2006.
33. Knee TS, Seidensticker DF, Walton JL, Solberg LM, Lasseter DH. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: A case series. Endocr Pract 9:181-186, 2003.
34. Lalej-Bennis D, Selam JL, Fluteau-Nadler S, M'Bemba J, Reach G, Slama G et al. Extreme insulin resistance: clinical management by external subcutaneous insulin infusion. Diabetes Metab 23:533-536, 1997.
35. Nathan DM, Axelrod L, Flier JS, Carr DB. U-500 insulin in the treatment of antibody-mediated insulin resistance. Ann Intern Med 94:653-656, 1981.
36. Lane W. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocrine Practice 12(3):251-256, 2006.
37. Hatipoglu B, Soni S, Espinsosa V. Glycemic control with continous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocrine Practice 12(5):542-544, 2006.
38. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG. U-500 insulin: Why, when and how to use in clinical practice. Diabetes/Metabolism Research and Reviews 23:265-268, 2007.
39. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988-1992, 1993.
40. Rosenstock J. Insulin therapy: optimizing control in type 1 and type 2 diabetes. Clin Cornerstone 4(2):50-64, 2001.